Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2012 | |
| Assets | |
| Current Assets | |
| Cash & Cash Equivalents | 718 |
| Receivables | 14 |
| TOTAL | $732 |
| Non-Current Assets | |
| PPE Net | 47 |
| TOTAL | $47 |
| Total Assets | $762 |
| Liabilities | |
| Current Liabilities | |
| Short Term Debt | 20 |
| Accounts payable and accrued liabilities | 400 |
| Other current liabilities | 90 |
| TOTAL | $513 |
| Non-Current Liabilities | |
| Other Non-Current Liabilities | 2,220 |
| TOTAL | $2,220 |
| Total Liabilities | $2,741 |
| Shareholders' Equity | |
| Retained earnings | -10,157 |
| Other shareholders' equity | 8,178 |
| TOTAL | $-1,979 |
| Total Liabilities And Equity | $762 |